Welcome to the KLK2-PASenger Study
A study for people with hormone resistant prostate cancer
that has spread to other parts of the body (metastasized).
Welcome to the KLK2-PASenger Study
A study for people with hormone resistant prostate cancer
that has spread to other parts of the body (metastasized).
The KLK2-PASenger Study is testing how safe and effective an investigational medication is for people with hormone-resistant prostate cancer that has spread to other parts of the body and is progressing. Hormone-resistant prostate cancer means the cancer is no longer responding to hormone therapy.
Everyone who participates in the study will be randomly assigned to receive the investigational medication with chemotherapy or chemotherapy alone, which is a standard of care treatment option for advanced prostate cancer.
The goal of this study is to test how well the investigational medication works with chemotherapy to stop or slow prostate cancer compared to chemotherapy alone. Though chemotherapy is an approved standard of care treatment option for metastatic prostate cancer, the combination with the investigational medication has not yet been approved.
Hormone-resistant metastatic prostate cancer (mHRPC) is an advanced stage of prostate cancer that has spread beyond the prostate gland to other parts of the body (metastatic). Prostate cancer cells often need a male hormone called testosterone to grow. Hormone-resistant prostate cancer means that the cancer cells have learned to grow even when the amount of testosterone in the body is very low.
Participants will be randomly assigned (like the flip of a coin) to get either the investigational medication with chemotherapy or chemotherapy alone. There is a 1 in 2 (50%) chance of receiving the investigational medication with chemotherapy, and a 1 in 2 (50%) chance of receiving chemotherapy alone.
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind: Even if you believe you meet the eligibility criteria, joining a clinical research study is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional. This questionnaire is intended for United States participants only.
Note about privacy: Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.